人β防御素3 融合蛋白在大肠杆菌中的表达、纯化与活性分析

近年来由于抗生素的不规范使用等多种原因,细菌耐药问题日益严重,人们正努力从各个方面来解决,其中机体天然产生的肽抗生素(peptide antibiotics)由于其对耐药菌的强大抗菌作用而受到人们的关注。肽抗生素是一种阳离子小分子多肽,在天然免疫和获得性免疫中都发挥着重要作用。防御素(defensin)是肽抗生素中较为重要的一种,主要来源于皮肤、呼吸道等的上皮组织,是正常机体抵抗外界病原微生物入侵的重要防线。人β防御素3(human betadefensin 3,hβD-3)参与人体免疫屏障,并因具有广谱抗菌和抗菌活性不被盐离子浓度抑制等特点而具特别的研究开发价值。提取中国人扁桃体组织总RNA,以RT-PCR技术扩增编码hβD-3成熟肽的cDNA并构建于原核表达载体pQE-80L,IPTG诱导表达后利用SDS-PAGE、免疫印记等方法对重组蛋白进行分析。重组蛋白表达量达到细菌表达总量的40%。重组蛋白自表达菌包涵体中提取后,经亲和层析法纯化目的蛋白达到电泳纯,经多步透析法复性,在体外抗菌实验中表现出了对金黄色葡萄球菌、多重耐药金黄色葡萄球菌等的抗菌活性,为进一步的研究和开发奠定了基础。     

大肠杆菌中融合表达人β防御素-3基因的研究

目的 为了在大肠杆菌中融合表达人β防御素-3基因。方法 根据大肠杆菌对精氨酸密码子使用的偏爱性,设计搭桥引物,并通过PCR扩增法合成了人β防御素的全基因序列,克隆进pGEX-4T-2中构建pGEX-4T-2-hBD-3融合表达载体。将表达载体转化E.coli宿主菌DH5α,进行IPTG诱导表达。将菌体反复冻溶使细胞膜穿孔,释放可溶性蛋白。融合蛋白GST-hBD-3经凝血酶切割。结果 研究得到了重组人防御素蛋白,琼脂孔穴扩散抑菌法检测表明,重组人β防御素3对金黄色葡萄球菌有抗菌活性,抑菌效价为0.843 U。结论 人β防御素-3基因在大肠杆菌中得到了融合表达。     

基于重组毕赤酵母的斑点叉尾鮰β-防御素表达

β-防御素是斑点叉尾鮰Ietalurus punetaus抵御病原微生物侵染的首要蛋白质免疫因子,其一级结构包含氨基端24个氨基酸组成的信号肽和羧基端43个氨基酸组成的成熟肽,该成熟肽赋予β-防御素的生物学活性。文中首次构建了产斑点叉尾鮰β-防御素的毕赤酵母Pichiapastoris重组菌株,实现了基于真核表达的斑点叉尾鮰β-防御素的生物合成。首先通过RT-PCR从斑点叉尾鮰皮肤中分离β-防御素成熟肽基因"IPBD",将其与表达载体p PICZαA连接并转入毕赤酵母X-33后,获得重组毕赤酵母菌株;经含1 000μg/m L博来霉素的培养基筛选,获得高拷贝重组菌株。以BMM培养基(无氨基氮源培养基)替代BMMY培养基(含氨基氮源培养基),对重组菌株的发酵培养条件进行优化,确定其产斑点叉尾鮰β-防御素的最适条件为:28℃、250 r/min、1.0%甲醇诱导表达96 h。重组菌株产物经镍离子亲和层析获得分子量为5.98k Da的纯化蛋白,基于MALDI-TOF-TOF的质谱分析证明该纯化蛋白为重组IPBD。抑菌活性测定结果表明重组IPBD对革兰氏阳性的金黄色葡萄球菌Staphylococcus aureus、单增李斯特菌Listeria monocytogenes以及革兰氏阴性的铜绿假单胞菌Pseudomonas aeruginosa的抑菌率分别为69.6%、71.6%和65.8%。本研究为鱼类来源天然小分子抗菌肽的开发提供了可参考的重组DNA技术。     

人β防御素3在大肠杆菌中可溶性表达及其生物活性的鉴定

根据大肠杆菌对精氨酸密码子使用的偏好,设计引物并通过酶促法合成了人β防御素3(hBD-3)全基因序列,克隆进pGEX-4T-2中构建pGEX-4T-2-hBD-3融合表达载体．将表达载体转化Ecoli宿主菌DH5α,进行IPTG诱导表达．控制诱导条件,提高可溶性蛋白的表达量．将菌体进行反复冻溶使细胞膜穿孔,释放可溶性蛋白．融合蛋白GST-hBD-3经凝血酶切割得到重组人防御素蛋白．用琼脂孔穴扩散抑菌法检测表明,重组人β防御素3对金黄色葡萄球菌有抑菌活性．     

重组人β防御素-3抗菌活性及其影响因素研究

采用琼脂扩散法对重组人β防御素-3(rhβD-3)的抗菌谱、最小抑菌浓度及其抗菌活性影响因素进行研究。结果表明,rhβD-3对G~+、G~-及真菌均有抑制作用。rhβD-3对金黄色葡萄球菌的最小抑菌浓度为15μg/mL,对大肠杆菌的最小抑菌浓度为20μg/mL。对rhβD-3的抗菌活性影响因素进行测定,结果表明rhβD-3在pH6.0时抗菌活性最高;而且在-70℃~100℃条件下仍具有较高的抗菌活性;在高于100 mmol/L NaCl浓度下,抗菌活性随着NaCl浓度的升高而降低。     

重组鹅β-防御素12蛋白的原核表达及生物学特性

【目的】研究重组鹅β-防御素12蛋白的原核表达并探究其生物学特性。【方法】采用His标签蛋白原核表达系统,将鹅防御素12(Av BD12)基因亚克隆到表达载体p Pro EX-HTa上,构建重组表达质粒。将重组表达质粒转化到大肠杆菌Rosseta感受态中,用IPTG进行诱导表达,并对该重组蛋白进行纯化。进一步采用菌落计数法测定其体外抗菌活性和盐离子稳定性。【结果】经Tricine-SDS-PAGE电泳分析,诱导表达的鹅Av BD12重组蛋白分子量约为12 k D,大部分以包涵体形式存在。该重组蛋白对大肠杆菌、鸡白痢沙门氏菌、金黄色葡萄球菌、四联球菌、枯草芽孢杆菌均具有抗菌活性,高浓度盐离子显著抑制重组蛋白的抗菌活性。此外,该重组蛋白对鸡红细胞没有溶血活性。【结论】该重组蛋白具有广谱抗菌活性,高浓度盐离子显著降低其抗菌活性,且该重组蛋白不具有溶解鸡红细胞的活性。     

β-防御素130在大肠杆菌中的串联表达、纯化及生物活性分析

为了研究抗菌肽β-防御素130的生物学活性和实现大规模制备,通过改良其分子结构,构建表达载体pET28a-3×β-defensin130,利用大肠杆菌BL21 (DE3)作为宿主细胞诱导表达后为水溶性蛋白。对纯化后抗菌肽进行抑菌实验、稳定性实验、MTT实验和溶血性实验确定其生物活性。最终成功制备出25 kDa的重组蛋白,对金黄色葡萄球菌(ATCC25923)(45μg/mL)和单增李斯特菌(ATCC221633)(80μg/mL)等革兰氏阴性和阳性菌都表现出极强的抗菌活性,且其抗菌活性不受温度、pH值和蛋白酶消化等影响,MTT细胞毒性实验显示其对HEK293细胞无毒性且对兔源红细胞具有极低的溶血性。这将为新型抗菌肽的开发提供理论基础并推动抗生素替代产业快速发展。     

羊胎小肠防御素的抗细菌作用研究

探讨防御素的抗细菌作用。用5%的乙酸抽提羊胎小肠细胞中的酸溶性成分,采用凝胶过滤层析获得羊胎小肠防御素,检测其对金黄色葡萄球菌、变形杆菌、枯草杆菌的抗菌活性。采用Sephadex G25凝胶过滤层析可获得纯化的羊胎小肠防御素。羊胎小肠防御素对金黄色葡萄球菌、变形杆菌有较强的抗菌活性,再但对枯草杆菌没有抗菌活性。     

人β-型肽抗生素研究进展

肽抗生素是生物体免疫防御系统的一个重要组成部分,有的为组成型表达,有的则只因微生物等因素的侵染而产生,肽抗生素带正电荷,对热稳定,具有广谱的抗菌活性,在迫切需要解决细菌对传统抗生素产生耐药性问题的今天,肽抗生素的研究为人类寻找新型的抗菌药物开辟了一条全新的道路。     

重组人β防御素3在大肠杆菌中的表达和活性分析

防御素是生物界广泛分布的一类低分子短肽,具有广谱高效的杀菌、抗肿瘤作用,并且不易使微生物产生抗药性,具有很高的应用价值,其中最引人注目的是β防御素[1,2].人β防御素3(humanβ-defensin3,hBD3)是最近发现的第3种人源性β防御素,与其它人防御素相比,在抗菌活性等方面具有明显优势,是所有防御素中抗菌能力最强的之一[3~7],具有独特的研究和开发价值.为了得到高效表达hBD3的工程菌株,本实验按照细菌对密码子的偏爱,人工合成了hBD3的寡核苷酸片段,构建了其表达载体.经IPTG诱导、分离纯化和肠激酶切割,得到了与天然hBD3活性基本相同的…     

一种抗菌肽和aFGF融合蛋白的构建和表达

利用PCR技术扩增出带有凝血酶Xa因子切割位点的天蚕素蜂毒素杂合肽和aFGF的融合基因,插入大肠杆菌表达载体pET-3c中,构建出表达质粒pET-aF-CM,并转化至大肠杆菌BL21（DE3）中,氨苄青霉素抗性筛选重组转化子。IPTG诱导4h后,以包涵体形式表达的融合蛋白约占菌体总蛋白的17%。将包涵体溶解后透析复性,并利用肝素亲和层析纯化,得到电泳纯的融合蛋白。Western blot分析表明,该蛋白能与aFGF抗体产生免疫反应。MTT法检测显示,融合蛋白具有促3T3Bal/b细胞分裂活性,其比活为1.471×106IU/mg。利用凝血酶Xa因子裂解融合蛋白,可以获得抗菌肽和含凝血酶Xa因子裂解序列的aFGF蛋白。分子筛回收含杂合抗菌肽,抑菌活性检测表明其对大肠杆菌K12D31具有明显抑菌活性。微量稀释法检测结果表明,回收的抗菌肽对大肠杆菌DH5α、大肠杆菌K12D31、沙门氏菌、金黄色葡萄球菌、枯草芽孢杆菌和绿脓杆菌的MIC分别达6.25μg/ml、10μg/ml、2.5μg/ml、1.25μg/ml、0.625μg/ml和5μg/ml。     

Novel anti-bacterial activities of β-defensin 1 in human platelets: suppression of pathogen growth and signaling of neutrophil extracellular trap formation

Human β-defensins (hBD) are antimicrobial peptides that curb microbial activity. Although hBD's are primarily expressed by epithelial cells, we show that human platelets express hBD-1 that has both predicted and novel antibacterial activities. We observed that activated platelets surround Staphylococcus aureus (S. aureus), forcing the pathogens into clusters that have a reduced growth rate compared to S. aureus alone. Given the microbicidal activity of β-defensins, we determined whether hBD family members were present in platelets and found mRNA and protein for hBD-1. We also established that hBD-1 protein resided in extragranular cytoplasmic compartments of platelets. Consistent with this localization pattern, agonists that elicit granular secretion by platelets did not readily induce hBD-1 release. Nevertheless, platelets released hBD-1 when they were stimulated by α-toxin, a S. aureus product that permeabilizes target cells. Platelet-derived hBD-1 significantly impaired the growth of clinical strains of S. aureus. hBD-1 also induced robust neutrophil extracellular trap (NET) formation by target polymorphonuclear leukocytes (PMNs), which is a novel antimicrobial function of β-defensins that was not previously identified. Taken together, these data demonstrate that hBD-1 is a previously-unrecognized component of platelets that displays classic antimicrobial activity and, in addition, signals PMNs to extrude DNA lattices that capture and kill bacteria.     

Functional expression,purification, and antimicrobial activity of a novel antimicrobial peptide MLH in Escherichia coli

In this study, a novel heterozygous antimicrobial peptide MLH was synthesized, expressed, purified, and characterized. The peptide Md-cec-LL-37_Hp (MLH) was selected through bioinformatic analysis using musca domestica antimicrobial peptide (Cec-Med), human antimicrobial peptide LL-37, and helicobacter pylori antimicrobial peptide (Hp) as parent peptides. The target gene was synthesized by overlap extension PCR (SOE-PCR) and connected to the expression vector pET-32a (+), and the recombinant plasmid pET-32a-MLH was transformed to Escherichia coli for constructing pET-32a-MLH/BL21 (DE3). Isopropyl β-D-thiogalactoside (IPTG) was used to induce protein expression, and SDS-PAGE and western blot were adopted to test the target protein. And fermentation condition was optimized to get the mass expression of the fusion protein. The Ni²⁺ affinity chromatographic column was used to purify. Active heterozygous peptide was obtained after renaturation. Finally, the activity of the heterozygous antimicrobial peptide was identified. The fusion peptide showed significant antimicrobial effect on both E. coli and Staphylococcus aureus.     

牛抗菌肽Bac7-Bac5融合基因在大肠杆菌中的过表达，纯化及抑菌活性

牛抗菌肽Bac7和Bac5是一种线性阳离子小分子多肽,在机体天然免疫和获得性免疫中都发挥着重要作用。本研究根据Gen bank中公布的牛抗菌肽bac7和bac5成熟肽基因序列,人工合成了融合基因Bac7-Bac5片段,克隆于原核表达载体pET32(a+)中构建了重组表达载体（pET-B7-B5）,将其转化于E coli BL21(DE3) 中实现了重组蛋白B7-B5（rB7-B5）的过表达,表达的rB7-B5以包涵体形式存在,rB7-B5表达量约占细菌总蛋白的36.6％,分子量大小为33kD,与预测大小相符。以经Ni亲和层析柱纯化和多步透析法复性的rB7-B5,对猪胸膜肺炎放线杆菌和耐药性大肠杆菌具有很好的抑菌活性,本研究为新型抗菌制剂的研制和开发奠定了基础。     

金黄色葡萄球菌肠毒素B基因的克隆和在大肠杆菌中高效表达

利用PCR方法从金黄色葡萄球菌TSTw基因组DNA中扩增出约700bp的DNA片段,将之克隆到pGEM7Zf(+)载体上并转化大肠杆菌 DH5α菌株。重组质粒的测序结果表明克隆到了seb基因,它含有717bp（不包括N端81bp的信号肽编码区）,其核苷酸序列与文献报道完全一致。将其连接于表达载体7ZTS上,转化到大肠杆菌JM109（DE3）内。表达的SEB占总蛋白33.5%。      

杂合抗菌肽在毕赤酵母中的表达及其活性测定

为获得溶血活性低、抗菌活性高的杂合抗菌肽,以家蝇抗菌肽Cec Md和中国林蛙抗菌肽Chensirin为母体肽,并结合毕赤酵母偏爱密码子的原则,设计出6条具有抗菌潜力的新型杂合抗菌肽,将其命名为CC22、CC28、CC29、CC30和CC34(1),CC34,利用SOE-PCR技术合成所需的目的基因,并将其克隆至毕赤酵母表达载体pGAPZαA,通过电击转化技术,将其转化至毕赤酵母SMD1168中,经含有Zeocin的抗性平板筛选阳性转化子,YPD液体培养72h后,经Tricine-SDS-PAGE检测出目的蛋白,然后采用高效液相色谱法对其进行纯化。检测结果显示,表达产物CC29对大肠杆菌、鸡沙门氏菌的最小抑菌浓度(MIC)均为25μg/ml;CC34(1)对大肠杆菌表现相对较弱的抑制作用,最小抑菌浓度为100μg/ml;CC34对鸡沙门氏菌和金黄色葡萄球菌的最小抑菌浓度为50μg/ml;且杂合抗菌肽对有益菌均没有表现出抑制作用。6条杂合肽的溶血活性均呈现较低水平,其中表现出抗菌活性的3条抗菌肽中,以CC29的溶血活性最低,CC34(1)和CC34相对次之。结合抑菌活性,CC29和CC34的抑菌效果较为明显,从而确定溶血活性低且抗菌活性较高的CC29和CC34为新型杂合抗菌肽。     

A flow cytometric assay to monitor antimicrobial activity of defensins and cationic tissue extracts

To determine the antibacterial activity of defensins and other antimicrobial peptides in biopsy extracts, we evaluated a flow cytometric method with the membrane potential sensitive dye bis-(1,3-dibutylbarbituric acid) trimethine oxonol [DiBAC4(3)]. This assay enables us to discriminate intact non-fluorescent and depolarized fluorescent bacteria after exposure to antimicrobial peptides by measurement at the direct target, the cytoplasmic membrane and the membrane potential. The feasibility of the flow cytometric assay was evaluated with recombinant human beta-defensin 3 (HBD-3) against 25 bacterial strains representing 12 species. HBD-3 showed a broad-spectrum dose dependent activity and the minimal dose to cause depolarization ranged from 1.25 to >15 microg/ml HBD-3, depending on the species tested. The antibacterial effect was diminished with sodium chloride or dithiothreitol and could be abrogated with a HBD-3 antibody. Additionally, isolated cationic extracts from human intestinal biopsies showed a strong bactericidal effect against Escherichia coli K12, E. coli ATCC 25922 and Staphylococcus aureus ATCC 25923, which was diminished towards E. coli at 150 mM NaCl, whereas the activity towards S. aureus ATCC 25923 remained unaffected at physiological salt concentrations. DTT blocked the bactericidal effect of biopsy extracts completely.     

人载脂蛋白AⅠ基因的克隆表达及功能

To identify, clone ,sequence and highly express the mature peptide gene of ApoA Ⅰ, total RNA was prepared from human fetal liver tissue. cDNA fragment encoding human ApoA Ⅰ was amplified by RT-PCR using specific primers, and then was inserted in pGEM-T vector. DNA sequencing indicates that the fragment is 729 base pairs in length and has 100% nucleotide homology with that of reported ApoA Ⅰ cDNA gene previously. The ApoA Ⅰ gene was cloned into pGEX 5X-1.The recombinant protein was expressed in E.coli DH5α, purified by glutathione-Sepharose 4B affinity chromatography and confirmed by SDS-PAGE. It was shown that the recombinant ApoA Ⅰ was expressed in E.coli, and the target protein amounted to 36% of total bacteria proteins. Cholesteryl ester transfer experiment showed that the recombinant ApoA Ⅰ was capable of promoting transfer of CE from HDL to LDL. Western blotting showed that the protein could react specifically with anti-ApoA Ⅰ antibodies.